News
The day at a glance · 4 min read
Mood · Risk-On
+65
Sentiment, −100 to +100
Moderna Stock Price
$173
Lilly Houston Plant Investment
$6.5B
J&J Orthopedics Unit Valuation
$20B
Key driverModerna's Phase 3 melanoma cancer vaccine data earning prestigious ESMO Presidential Symposium slot drove biotech momentum, while market research highlighted strong growth trajectories across orphan drugs, PEGylated proteins, and drug discovery informatics segments
Daily briefHealthcare· Money365.Market AI ·

Moderna Surges on Cancer Vaccine Data; Industry Eyes Growth

MRNA jumps on melanoma trial results earning ESMO slot; orphan drug market projected to double by 2030; J&J explores orthopedics sale

Big Pharma & Biotech

Bullish
MRNAABBVLLYJNJMRK
Moderna (MRNA) shares jumped to $173 after positive Phase 3 INTerpath-001 trial results for its personalized cancer vaccine, intismeran autogene, alongside Merck's (MRK) Keytruda in high-risk melanoma patients earned a spot in the European Society for Medical Oncology's Presidential Symposium on October 24. The FDA also cleared Moderna's updated Spikevax and mNEXSPIKE shots targeting new variants.
AbbVie (ABBV) announced European Commission approval of RINVOQ (upadacitinib; 15 mg tablet and weight-based 1 mg/mL oral solution) for the treatment of active polyarticular juvenile idiopathic arthritis in patients two years of age and older who have responded inadequately to, or are intolerant to, one or more disease-modifying anti-rheumatic drugs. RINVOQ may be used as monotherapy or in combination with methotrexate.
Eli Lilly (LLY) CEO reported that about one-third of new patients starting a GLP-1 tablet are now on Foundayo, with the company's share of the oral market still rising week by week. The company broke ground on a $6.5B manufacturing plant in Houston to support GLP-1 production capacity.
Johnson & Johnson (JNJ) is exploring the potential sale of its orthopedics unit for $20 billion as the healthcare giant seeks to become a more profitable and faster-growing business through strategic portfolio reshaping.

Biopharma Market Opportunities

Bullish

Orphan Drugs Market 2024

$216.3B+12% CAGR

Orphan Drugs Market 2030

$426.2B

PEGylated Proteins Market 2025

$2.0B+10.6% CAGR

PEGylated Proteins Market 2032

$4.1B

Drug Discovery Informatics 2025

$4.0B+11.9% CAGR

Drug Discovery Informatics 2032

$8.7B
PFEAMGNTMO
The global market for orphan drugs was valued at $216.3 billion in 2024 and is projected to reach $426.2 billion by 2030, growing at a CAGR of 12%. Demand is rising as genomics, biologics and personalized therapies advance, aided by faster approvals, government incentives, advocacy and improved rare-disease diagnosis, creating opportunities for companies including Novartis, Roche, Pfizer (PFE), Sanofi and AstraZeneca.
The global market for PEGylated proteins was estimated at $2.0 billion in 2025 and is projected to reach $4.1 billion by 2032, growing at a CAGR of 10.6%. Site-specific PEGylation is enabling safer, longer-acting biologics, while demand in chronic disease, targeted therapies and biosimilars creates opportunities for services and reagents, with key players including Amgen (AMGN), Roche, Merck KGaA, Pfizer and Novo Nordisk.
The global market for drug discovery informatics was estimated at $4.0 billion in 2025 and is projected to reach $8.7 billion by 2032, growing at a CAGR of 11.9%. AI, machine learning and big data are advancing virtual screening and precision medicine, creating opportunities in molecular modeling, docking and data integration for companies including Schrödinger, Certara, Dotmatics, Thermo Fisher Scientific (TMO) and BIOVIA.

MedTech & Diagnostics

Bullish

High-Content Screening 2024

$1.3B

High-Content Screening 2030

$2.2B

Aseptic Sampling Market 2025

$867.4M+6.3% CAGR

Aseptic Sampling Market 2032

$1.3B
TMO
Tempus AI founder and CEO reported the company's second-quarter performance was supported by continued demand for comprehensive genomic profiling and growth in its data-licensing business at the Morgan Stanley Global Healthcare Conference. The diagnostics company highlighted pricing and data growth as key drivers fueling long-term expansion.
The global market for high-content screening was valued at $1.3 billion in 2024 and is projected to reach $2.2 billion by 2030. High-content screening is advancing drug discovery and personalized medicine, driven by 3D models, advanced imaging and automated analytics, with opportunities in cancer research and organoids for companies including Thermo Fisher Scientific (TMO), Danaher, Revvity and Yokogawa.
The global market for aseptic sampling was estimated at $867.4 million in 2025 and is projected to reach $1.3 billion by 2032, growing at a CAGR of 6.3%. Demand is rising for single-use, automated and real-time aseptic sampling as biopharma and food producers prioritize contamination control, continuous manufacturing and compliance, with key players including Merck KGaA, Sartorius, Thermo Fisher Scientific, Danaher and GEA.

Looking Ahead

Neutral
MRNALLY
AlzeCure Pharma announced participation at Swiss Nordic Bio 2026 in Zurich on October 1, a partnering and investor conference connecting Nordic, Swiss and Austrian companies in biotech, medtech and pharma with global investors and industry representatives. The company develops small-molecule drug candidates for CNS diseases with a focus on Alzheimer's disease and pain.
Moderna (MRNA) is scheduled to present Phase 3 data for intismeran autogene at the ESMO Presidential Symposium on October 24, representing a high-profile forum for presenting breakthrough cancer treatment data to the European oncology community.

Important Disclaimer — Not Investment Advice

Disclaimer: This article is provided by Money365.Market for general information and educational purposes only. It is not financial advice, a personal recommendation, or an inducement to buy, sell, or invest in any security or product. Capital is at risk and the value of investments can go down as well as up; past performance does not indicate future results. You should seek independent advice from an FCA-authorised adviser before making any financial decision.

Read the full disclaimer — 8 further points, including total-loss risk, our regulatory status and conflicts of interest

Nothing here is an offer or a solicitation to buy or sell anything, and reading it creates no advisory or fiduciary relationship between you and Money365.Market. Any decision you take is your own.

  • You can lose money — including all of it. Individual companies can and do fail, and some of the assets discussed can fall to zero. Only commit money you can afford to lose, and never borrow to invest on the strength of anything you read here.
  • Forecasts are opinion, not fact. Any valuation model, scenario, fair-value range, estimate or other forward-looking statement is illustrative, rests on assumptions that may prove wrong, and is never a price target, a forecast of actual outcomes, or a promise of any return.
  • Published at a point in time. Figures were believed accurate on the publication or last-updated date shown above and are not maintained afterwards; we are under no obligation to update them. Market and company data comes from third-party sources and is provided without warranty of accuracy, completeness or timeliness.
  • Automated content. This brief was compiled by an automated pipeline from validated news and market-data sources and passed through editorial and compliance checks. Automated content can still contain errors — verify anything you intend to rely on.
  • We are not regulated. Money365.Market is not authorised or regulated by the UK Financial Conduct Authority, is not registered with the U.S. Securities and Exchange Commission or FINRA as an investment adviser or broker-dealer, and is not a tax adviser. We hold no licence to give personal financial advice and do not do so.
  • Interests and independence. Money365.Market is not affiliated with, endorsed by or sponsored by any company, fund, exchange or platform mentioned, and is not paid to feature them. The author may hold positions in securities or assets discussed. The site earns revenue from advertising, subscriptions and, where labelled, affiliate links; this does not influence what we publish.
  • Your jurisdiction matters. Tax treatment, contribution limits, product availability and investor protections differ by country and can change. Speak to a qualified tax professional for tax matters, and to a locally licensed adviser if you are outside the UK.

Full terms: Disclaimer · Terms of Service · Privacy Policy